Maintain pressure on reforms to protect NHSAdded kidney benefit from tight HbA1c control
They studied 11,140 patients, of which half received intensive glucose control – using a modified release version of the sulfonylurea gliclazide plus other drugs as required to achieve an HbA1c of 6.5% – and the rest received standard control.
After five years, researchers found those in the intensive control group were 21% less likely to suffer from new or worsening nephropathy compared to the control group, whose average HbA1c was 7.3%.
‘The clear reduction in nephropathy is important because indexes of renal impairment are strongly associated with the future risk of major vascular events, end-stage renal disease, and death in patients with diabetes,’ the authors said online in the New England Journal of Medicine.
Online training units, written and reviewed by experts. Earn two hours' CPD and a personalised certificate for your portfolio.
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Share
Have your say
You must sign in to make a comment.